A tumor board puts every discipline on a hard case at one table, arguing it out before anyone commits. Delibera brings that structure to the treating physician, starting with GU cancers.
We came to it sideways. Delibera began as a general tool for structured deliberation: several perspectives argue the same question, and their disagreements stay on the record. A clinician who ran patient cases through it asked why we didn’t turn it into a tumor board, and in 2026 we rebuilt Delibera around that question. We live and work in central Washington, inside the WWAMI region where we are starting.
Co-founder and chief executive
Justin’s father died of a brain tumor, and his career began at the Leukemia & Lymphoma Society. He went on to brand marketing for REI, Eddie Bauer and evo, and in 2017 bought a backcountry adventure tourism company, which he grew and sold in 2025. He leads strategy and go-to-market at Delibera.
Co-founder and chief technology officer
Dave has spent twenty years in systems architecture, cybersecurity and compliance, including security programs for Fortune 20 financial services, telecom and technology organizations and FedRAMP, SOC 2 Type II and ISO 27001 work. His background includes Joint Special Operations communications. He holds the CISSP and builds Delibera's platform and its security program.
Chief clinical advisor
Michael is an Advanced Practice Provider and Teaching Associate at Fred Hutchinson Cancer Center and University of Washington Medical Center, sub-specializing in genitourinary medical oncology. For the past decade, he has cared for patients from locally advanced disease through metastatic and end-of-life settings. He is a sub-investigator on numerous Phase 1b–3 clinical trials, many of which led to FDA-approved therapies, including enfortumab vedotin and lutetium-177 PSMA, and a co-author on the associated research. He has been invited faculty at national conferences including JADPRO Live and ONS Congress. Michael reviews Delibera's outputs and authored the protocol for its clinical evaluation.
We read every request ourselves and will get back to you within two business days.
Request access